An interventional study of Peripheral Perfusion Index-guided Fluid Resuscitation Protocol and Conventional Goal-Directed Fluid Resuscitation in Sepsis, Septic Shock and Acute Skin Failure, sponsored by Ying Wang. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Ying Wang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.
Among the 89 studies in Shock, Septic with a site in China, this one is the 19th largest by planned enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2025, is one of 41 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 74th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–90
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 4 · Phase 4 11
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 72 across the 62 interventional studies, 148 across the 26 observational. Of the 33 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 89 have an industry lead sponsor. The 10 most frequent:
Ying Wang is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ying Wang has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
12 of the studies in Shock, Septic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT06692036Beijing Chao Yang HospitalAdaptive Blood Purification for the Treatment of Patients With Septic Shock | 2026-12-31 |
| NCT06990295First Affiliated Hospital of Wannan Medical CollegeFocused Ultrasound Spleen Stimulation and Inflammation in Septic Shock | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 89 studies in Shock, Septic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, controlled trial aimed to evaluate whether fluid resuscitation guided by the Peripheral Perfusion Index (PPI) could reduce the incidence of Acute Skin Failure (ASF) in elderly critically ill patients. A total of 216 patients aged ≥65 years with sepsis or other types of shock requiring early aggressive fluid resuscitation were enrolled and randomly assigned in a 1:1 ratio to either the PPI-guided resuscitation group or the conventional resuscitation group. The intervention group targeted maintaining PPI ≥1.4 in addition to conventional hemodynamic goals, while the control group followed standard resuscitation protocols. The primary outcome was the incidence of ASF within 7 days of ICU admission, diagnosed according to NPUAP/EPUAP (2014) criteria. Secondary outcomes included time to ASF occurrence, lactate clearance, cumulative fluid balance, organ function, and long-term prognosis.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 216 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Ying Wang is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Peripheral Perfusion Index-guided Fluid Resuscitation Protocol
Other: Conventional Goal-Directed Fluid Resuscitation
In addition to achieving conventional macro-hemodynamic goals (mean arterial pressure ≥65 mmHg, etc.), a resuscitation protocol targeting a Peripheral Perfusion Index (PPI) value ≥1.4 is implemented. PPI is continuously monitored via a finger pulse oximeter. If PPI remains below 1.4 for \>30 minutes, a fluid responsiveness assessment (e.g., passive leg raising test) is performed. Fluid boluses (balanced crystalloid) are administered only if the patient is fluid-responsive. Otherwise, vasoactive agents are optimized.
Fluid resuscitation is performed according to the Surviving Sepsis Campaign International Guidelines. Resuscitation targets include: mean arterial pressure ≥65 mmHg, central venous pressure 8-12 mmHg, urine output ≥0.5 mL·kg-¹·h-¹, and normalization/decreasing trend of serum lactate. The type, rate, and volume of fluid administration are determined by the treating physician based on these standard macro-hemodynamic and perfusion parameters.
Incidence of Acute Skin Failure(per the NPUAP/EPUAP 2014 Guidelines)
Proportion of patients who develop new-onset Acute Skin Failure (ASF) within 7 days after ICU admission. ASF is diagnosed and staged according to the NPUAP/EPUAP (2014) criteria.
Time frame: From ICU admission up to 7 days
Time to Acute Skin Failure (ASF) Onset
Number of days from ICU admission to the first diagnosis of ASF (assessed in patients who develop ASF)
Time frame: From ICU admission up to 7 days
Maximum Stage of Acute Skin Failure
The most severe stage of ASF (according to NPUAP/EPUAP 2014 criteria) observed within 7 days after ICU admission
Time frame: From ICU admission up to 7 days
Lactate Clearance Rate at 6 Hours
Percentage decrease in serum lactate concentration from baseline to 6 hours after initiation of resuscitation
Time frame: Baseline and 6 hours after resuscitation initiation
Lactate Clearance Rate at 24 Hours
Percentage decrease in serum lactate concentration from baseline to 24 hours after initiation of resuscitation
Time frame: Baseline and 24 hours after resuscitation initiation
Cumulative Fluid Balance at 72 Hours
Net fluid balance (total fluid intake minus total output) calculated over the first 72 hours of ICU stay
Time frame: From ICU admission up to 72 hours
Incidence of Acute Kidney Injury
Proportion of patients who develop AKI according to KDIGO criteria within 7 days after ICU admission
Time frame: From ICU admission up to 7 days
Duration of Mechanical Ventilation
Total number of days requiring invasive mechanical ventilation during ICU stay
Time frame: From ICU admission until ICU discharge, up to 90 days
Length of ICU Stay
Total number of days from ICU admission to ICU discharge
Time frame: From ICU admission until ICU discharge, up to 90 days
28-Day All-Cause Mortality
Proportion of patients who die from any cause within 28 days after ICU admission
Time frame: From ICU admission up to 28 days
90-Day All-Cause Mortality
Proportion of patients who die from any cause within 90 days after ICU admission
Time frame: From ICU admission up to 90 days
Barthel Index at Hospital Discharge
Score of the Barthel Index (a measure of activities of daily living) assessed at the time of hospital discharge in surviving patients. Range: 0-100, higher scores indicate greater independence
Time frame: At hospital discharge, up to 90 days after ICU admission
Total Hospitalization Costs
Total direct medical costs incurred during the index hospitalization, expressed in local currency
Time frame: From hospital admission to hospital discharge, up to 90 days
30-Day Unplanned Readmission Rate
Proportion of patients who have an unplanned readmission to any hospital within 30 days after hospital discharge
Time frame: 30 days after hospital discharge
Incidence of Resuscitation-Related Serious Adverse Events
Proportion of patients who experience serious adverse events related to fluid resuscitation (e.g., new-onset cardiogenic pulmonary edema, arrhythmia requiring intervention) during the ICU stay
Time frame: From ICU admission until ICU discharge, up to 90 days
Plan to share: No — The investigators may have further research, and the investigators may not consider releasing the research data until the results are announced
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 23 months is close to that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.